Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Translationally controlled tumor protein (TCTP), also referred to as HRF or fortilin, is a multifunctional protein, expressed in all eukaryotic organisms from protozoa to humans. TCTP is involved in many basic biological processes, such as cell division, growth, and development. It is therefore not surprising that dysregulation of TCTP occurs in various disease processes, such as cardiovascular, allergic, and immune disorders. TCTP’s role in cancer-promoting pathways is well- documented, and the protein is considered a potential target for the design of new anti-cancer strategies. Therefore, an understanding of the core biological functions of TCTP, the mechanisms underlying its cellular regulation, and its involvement in disease processes is important. This book provides a current overview on the basic biological functions of TCTP and on its role in promoting a range of disease processes.

Research & information: general --- Biology, life sciences --- Loxosceles --- brown spider --- TCTP --- venom --- toxin --- HRF --- allergy --- mast cells --- basophils --- IgE --- FcεRI --- translationally controlled tumor protein (TCTP) --- apoptosis --- conditional knockout mice --- development --- Nestin-cre --- neurogenesis --- neuronal progenitor cells --- perinatal death --- proliferation --- Mmi1 --- translationally controlled tumor protein --- autophagy --- reactive oxygen species --- rapamycin --- nitrogen starvation --- cancer --- phospho-TCTP --- DHA --- T-DM1 --- HER2-positive breast cancer --- TCTP (HRF --- fortilin) --- growth and development --- biological stress reactions --- regulation of protein synthesis --- regulated protein degradation --- cardiovascular diseases --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Treatment strategies for breast cancer are wide-ranging and often based on a multi-modality approach, depending on the stage and biology of the tumour and the acceptance and tolerance of the patient. They may include surgery, radiotherapy, and systemic therapy (endocrine therapy, chemotherapy, and targeted therapy). Advances in technologies such as oncoplastic surgery, radiation planning and delivery, and genomics, and the development of novel systemic therapy agents alongside their evaluation in ongoing clinical trials continue to strive for improvements in outcomes. In this Special Issue, we publish a collection of studies looking at all forms of therapeutic strategies for early and advanced breast cancer, focusing on their outcomes, notably survival.

relative survival --- young women --- cancer treatment --- n/a --- fulvestrant --- lapatinib --- tumor biology --- antihormone therapy --- mastectomy --- aromatase inhibitors --- chemotherapy --- serum biomarker --- cyclin E --- anthracycline resistance --- zero-inflated Poisson regression model --- lymph-node ratio --- CHEK2 --- comparative effectiveness --- breast-conserving therapy --- taxane sensitivity --- liquid biopsy --- HER2 c-erbB2 --- colorectal cancer --- infiltrating breast cancer --- survival --- exercise characteristics --- lactate dehydrogenase --- biomarker --- breast cancer survivors --- BRCA --- disease-free survival --- PIK3CA --- metastatic breast cancer --- cell-free DNA --- invasive breast cancer --- radiotherapy --- Metformin --- social well-being --- gene expression --- contralateral breast cancer --- basal-like breast cancer --- LMK-235 --- Src kinase --- HER2/neu --- LKB1 --- Older women --- LDH --- mutation carriers --- stage IV --- mammography screening --- NCDB --- cMet --- SEER --- pertuzumab --- physical function --- outcome --- ribociclib --- older patients --- geriatric oncology --- metastatic --- overdiagnosis --- next-generation sequencing --- abemaciclib --- Endocrine therapy --- monitoring metastatic breast cancer --- breast cancer --- circulating tumor cells --- Breast Cancer --- PALB2 --- histone deacetylase --- prognosis --- physical activity --- trastuzumab --- ductal carcinoma in situ --- contralateral prophylactic mastectomy --- ERCC1 --- family history --- T-DM1 --- ATM --- advanced breast cancer --- incidence --- palbociclib --- HDAC5 inhibitors --- APOBEC3B